

Updates on Advanced Breast Cancer: Local Management and Other New Perspectives 2023

5/12/2023 - 5/13/2023

7:30 AM - 1:00 PM

Target Audience:

Specialties: Internal Medicine, Medical Oncology, Surgery
Professions: Physician (MD or DO), Physician Assistant, Social Worker, Student or Trainee, Other

Description:

This educational activity aims to enhance the knowledge of oncologists in the management of advanced breast cancer and how to implement the emerging therapies and cutting-edge techniques into day-to-day practice. This activity will present the latest research updates and treatment trends/guideline for triple-negative breast cancer, inflammatory breast cancer, locally advanced breast cancer and metastatic breast cancer. Experts from both inside and outside of MD Anderson will address the importance of applying a multidisciplinary team approach to develop methods for identification of specific genomic and proteomic signatures of breast cancer. Clinical scenarios will be discussed to provide examples of a high level of patient-focused, multidisciplinary care a breast cancer patient should receive. Experts will also present on current clinical trials that offer novel therapies to treat advanced, rare, and aggressive breast cancers. The goal is for healthcare professionals to develop the tools to diagnose, identify therapeutic approaches specifically for treatment of breast cancer, enhance approaches to assist in detecting the disease evaluate the effectiveness of treatment for advanced breast cancer patients, and appropriately refer patients to clinical trials if needed after the understanding of available therapy.

Learning Objectives:

1. Recognize inflammatory and triple-negative breast cancer and provide appropriate delivery of therapy that involves multidisciplinary care.
2. Develop skills in patient advocacy and support.
3. Implement the latest management techniques for locally advanced and recurrent breast cancer cases in their practice.
4. Integrate the latest biological discoveries and genomic findings into their clinical practice to improve patient outcomes.

Accreditation:



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.00 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Eric Gagneaux	Activity Administrator	Nothing to disclose - 12/26/2022
Marcella Sanchez	Activity Coordinator	Nothing to disclose - 12/28/2022
Karin Woodman, MD	CE Reviewer	Nothing to disclose - 02/13/2023
Bora Lim, MD	Co-Director, Faculty	Nothing to disclose - 01/05/2023
Mediget Teshome, MD	Co-Director, Faculty	Other: travel/accommodations support for conference-Endomagnetics LTD (Relationship has ended) - 03/27/2023
Taiwo Adesoye, MD	Faculty	Nothing to disclose - 03/16/2023
Charu Agrawal, MD	Faculty	Nothing to disclose - 04/18/2023
Carlos H Barcenaz, MD	Faculty	Nothing to disclose - 03/08/2023
Vivian Bea, MD, FACS	Faculty	Grant or research support-Pfizer Inc. (Relationship has ended) Consulting Fee-American Cancer Society Consulting Fee-Allegan Aesthetics - 04/17/2023
Isaac Chan, MD, PhD	Faculty	Nothing to disclose - 03/31/2023
Jenny C. Chang, MD, MBA	Faculty	Consulting Fee-Lilly USA, LLC (Relationship has ended) Consulting Fee-AstraZeneca US (Relationship has ended) Consulting Fee-Merck Sharp & Dohme Corp. (any division) (Relationship has ended) - 03/07/2023
Jeffrey Chuang, PhD	Faculty	Nothing to disclose - 03/13/2023
Deborah Clemens	Faculty	Nothing to disclose - 05/03/2023
Senthil Damodaran, MD, PhD	Faculty	Nothing to disclose - 04/03/2023
Gloria V Echeverria, PhD	Faculty	Nothing to disclose - 03/07/2023
Leisha C Elmore, MD	Faculty	Nothing to disclose - 03/21/2023
Jeremy Force, DO	Faculty	Grant or research support-Xilis Advisor-Pfizer Inc. Advisor-Novartis Pharmaceuticals Corporation Advisor-Nanostring Advisor-Guardant Health Paid consultant-Exact Sciences Paid consultant-Gilead Sciences, Inc. Paid consultant-PRIME Paid consultant-Clinical Care Options Paid consultant-Practicing Clinicians Exchange Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants Grant or research support-Xilis - 04/17/2023
Alex Frenzel	Faculty	Nothing to disclose - 04/27/2023
Ana C Garrido-Castro, MD	Faculty	Grant or research support-AstraZeneca US Grant or research support-Zenith Epigenetics Grant or research support-Gilead Sciences, Inc. Grant or research support-Merck Sharp & Dohme Corp. (any division) Grant or research support-Daiichi Sankyo, Inc. Other: Travel accommodations (scientific meeting)-Roche/Genentech (Relationship has ended) Grant or research support-Bristol-Myers Squibb Company Grant or research support-Novartis Pharmaceuticals Corporation - 04/02/2023
Antonio Giordano, MD, PhD	Faculty	Advisor-Pfizer Inc. (Relationship has ended) - 04/01/2023
Valentina Hoyos, MD	Faculty	Royalties or Patent Beneficiary-Takeda Pharmaceutical (Relationship has ended) Stocks or

		stock options, excluding diversified mutual funds-Allovir Stocks or stock options, excluding diversified mutual funds-Marker Therapeutics - 04/17/2023
Monica L Huang, MD	Faculty	Grant or research support-Boston Scientific Corporation - 04/12/2023
Meghan Karuturi, MD	Faculty	Paid consultant-Pfizer Inc. - 12/26/2022
Virginia Kirklin, MPH	Faculty	Nothing to disclose - 04/14/2023
Alphi Kuriakose, BS	Faculty	Nothing to disclose - 04/16/2023
Ellen Manzullo, MD	Faculty	Nothing to disclose - 04/27/2023
Zayd Razouki, MD	Faculty	Nothing to disclose - 01/10/2023
Guangwen Ren, PhD	Faculty	Nothing to disclose - 03/16/2023
Evanthia Roussos Torres, MD, PhD	Faculty	Paid consultant-Synaptical Inc - 03/16/2023
Ajay Sheshadri, MD	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Enanta Pharmaceuticals - 01/10/2023
Rahul Sheth, MD	Faculty	Consulting Fee-Trisalus Grant or research support-Boston Scientific Corporation Consulting Fee-Medtronic, Inc. (any division) Consulting Fee-Replimune Consulting Fee-Varian Medical Systems, Inc - 03/22/2023
Michael C Stauder, MD	Faculty	Nothing to disclose - 11/30/2022
Susie Sun, MD	Faculty	Nothing to disclose - 10/07/2022
Olympia Valadez, N/A	Faculty	Nothing to disclose - 04/29/2023
Clinton Yam, MD	Faculty	Grant or research support-GlaxoSmithKline Grant or research support-Gilead Sciences, Inc. Grant or research support-BostonGene Grant or research support-Amgen Inc. Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants Grant or research support-Novartis Pharmaceuticals Corporation Grant or research support-Pfizer/Astellas Advisor-Gilead Sciences, Inc. - 04/26/2023
Abbey J Kaler, MS, MS, APRN, FNP-C, CMSRN	Faculty, Other Planning Committee Member	Nothing to disclose - 01/05/2023

REQUIREMENTS FOR SUCCESSFUL COMPLETION

To claim CE credits or contact hours for this activity, the participant must:

- Professional Education Portal (PEP)**
 - Create an account and complete profile in (PEP).
 - Profiles need to include the following Degree, Profession, email address and mobile number
 - Pair your email address to PEP (must use email address used to create PEP account). This is a **one-time** only process to allow you to log your attendance using the text messaging feature. Pairing your phone to the system is done by sending a **text** of your **email address** to **1-844-912-1333**.
- Attend the Entire Activity**
Record Attendance: During the activity, the learner will TEXT the code provided during the activity to **1-844-912-1333 (texting to record attendance only needs to be done once for the duration of the activity)**. Learners will have up to 24 hours after the activity has ended to text this code to have their attendance recorded.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

The University of Texas MD Anderson Cancer Center and the conference organizing committee wishes to express appreciation to the following companies for their commitment by providing commercial support of this continuing education activity.

EDUCATIONAL GRANTS

AstraZeneca Pharmaceuticals

Novartis Pharmaceuticals Corporation

This Acknowledgement recognizes confirmed supporters and exhibitors as of May 8, 2023.

EXHIBITORS/SPONSORS

The University of Texas MD Anderson Cancer Center and the conference organizing committee wishes to express appreciation to the following companies for exhibiting and/or sponsoring this continuing educational activity.

Daiichi Sankyo, Inc.

Eli Lilly and Company

Exact Sciences

Gilead Sciences

IBC Network Foundation

Merck

Novartis Pharmaceuticals Corporation

Pfizer Inc.

Seagen

Stemline Therapeutics

This Acknowledgement recognizes confirmed supporters and exhibitors as of May 8, 2023.